FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow
The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Specifically tailored to workflows for nuclear medicine and molecular imaging, the InterView™ Fusion (Mediso) and InterView XP (Mediso) multimodality (PET/SPECT/MRI/CT) image processing and reporting software have garnered 510(k) clearance from the Food and Drug Administration (FDA).
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including cardiac, bone, thyroid, liver, and lung imaging, according to Mediso.
The company said the InterView software also features a variety of modules that facilitate automated lesion detection and segmentation as well as image denoising.
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including bone imaging. (Images courtesy of Mediso.)
Mediso added that the vendor independent software can be utilized on stand-alone workstations or be incorporated seamlessly into physical or virtual servers of hospital information systems.
“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application, and they demonstrate our continuous commitment to the molecular imaging market,” noted Istvan Bagamery, the founder and CEO of Mediso.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
